Pfizer

Q3 2026
Speakers

Nov 3, 2026 · 73 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Good day, everyone, and welcome to Pfizer's third quarter 2026 earnings conference call. Today's call is being recorded. ?At this time, I would like to turn the call over to Francesca DiMartino, Chief Investor Relations Officer and Senior Vice President. Please go ahead, ma'am.

Passages & reports (3)
  • Good day, everyone, and welcome to Pfizer's third quarter 2026 earnings conference call. T…
  • At
  • this time, I would like to turn the call over to Francesca DiMartino, Chief Investor Relat…

Speaker 1

Unverified voice label

Good morning and welcome to Pfizer's Earnings Call. ?I'm Francesca DiMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, thank you for joining ?us. This call is being made available via audio webcast at Pfizer.com. Earlier this morning, we released our results for the third quarter 2026 via a press release that is available on our website at Pfizer.com. I'm joined today by Dr.

Albert Borla, our chairman and CEO, Cecile Gagon, our CFO, and
Chris Boschoff, our scientific, our chief scientific officer. After their prepared remarks, we will open the call for questions. Members of our leadership team will be available for the QA session. Before we get started, I want to remind you that we will be making forward-looking statements and discussing certain non-GAP financial measures. ?I encourage you to read the disclaimers in our slide presentation, ?the press release we issued this morning, and the disclosures in our SEC filings, which are all available on the IR website on Pfizer.com.

Forward-looking statements on the call are subject to substantial risks and uncertainty, speak only as of the call's original date, and we undertake no obligation to update or revise any of
the statements. With that, I will turn the call over to Albert.

Passages & reports (11)
  • Good morning and welcome to Pfizer's Earnings Call.
  • I'm
  • Francesca DiMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, thank…
  • us.
  • This call is being made available via audio webcast at Pfizer.com. Earlier this morning, w…
  • Chris Boschoff, our scientific, our chief scientific officer. After their prepared remarks…
  • I
  • encourage you to read the disclaimers in our slide presentation,
  • the
  • press release we issued this morning, and the disclosures in our SEC filings, which are al…
  • the statements. With that, I will turn the call over to Albert.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 2

Unverified voice label

you, Francesca. Good morning, everyone, and thank you for joining our call. I'm pleased with another strong quarter for Pfizer. Our excellent commercial execution, including 32% operational revenue growth in the quarter for our launched and acquired products, shows the underlying strength of our business. Financial discipline and ongoing productivity improvement are driving efficiency and contributing favorably toward our margins. And with continued progress of our high value RD programs, we believe that we are on a pathway to the next stage of meaningful growth.

Before going further, I want to welcome Cecile Guegang as our chief financial officer. Cecile brings more than 25 years of finance leadership and the proven ability to deliver new sources of growth. She stood out in a global search for
her expertise, her deep knowledge of Pfizer and our industry, and a strategic vision that I believe will help Pfizer unlock sustained long-term value ?for patients and shareholders.

I'm looking forward to Cecile's partnership, and I'm confident she will help us execute with the discipline and ambition this next chapter requires. Now let me cover several highlights of our progress in this quarter. As you know,
over the last few years, we have invested close to $80 billion in transactions that have equipped us with key products, contributing to current commercial momentum and platforms with transformative potential.

About 80% of this investment was for Sidgen,
Mechera, and Bioheaven. And we are making good progress in maximizing the value of each one. We are pleased with the overall performance of our acquired products, which grew 37% operationally in this quarter. Our legacy seed gen portfolio grew 39% year over year in the US, in the quarter, driven by the strong performance of PATSE.

Bringing season's medicines together with the strengthened reach of our commercial organization has deepened our presence in the oncology community. We now offer physicians and care teams
a broader set of options and more expertise, helping patients and driving growth for Pfizer. SIGEN did more than strengthen our commercial position. It also expanded our ability to discover oncology breakthroughs, doubling the size of our early stage pipeline at the time we closed the acquisition.

In our late-stage development programs, we are advancing potential antibody drug conjugates that could bring meaningful improvements for patients with cancer. I'm pleased with the pace of progress over the past year with our
expensive clinical development program across our obesity portfolio. We plan to advance 10 active and planned phase three trials in 2026, including one evaluating a switch from approved weekly therapies to our investigational monthly GLP1 peptide berobenatide.

We have made significant progress with enrolment across our pivotal berobenatide program, as well as our amylin combination program, where our phase 2B study is now fully enrolled.
?We are working toward the first in a series of potential approvals for berobenatite in 2028. with planning of our go to market strategy well underway. Bioheaven also has been a strategically important addition for Pfizer. In the quarter, Nurtec grew by 33% operationally, driven by underlying demand and excellent commercial execution.

We see real opportunity to help patients with migraine and for the oral CGRP class to be a key growth driver, even as we market dynamics in a competitive
field. We are leading the oral CGRP class in the US and are working to extend that position internationally. We are seeing international growth as more patients can now get this treatment in key countries, including the UK, Italy, and Japan.

Passages & reports (17)
  • you, Francesca. Good morning, everyone, and thank you for joining our call. I'm pleased wi…
  • Financial discipline and ongoing productivity improvement are driving efficiency and contr…
  • meaningful growth. Before going further, I want to welcome Cecile Guegang as our chief fin…
  • her expertise, her deep knowledge of Pfizer and our industry, and a strategic vision that …
  • for
  • patients and shareholders. I'm looking forward to Cecile's partnership, and I'm confident …
  • over the last few years, we have invested close to $80 billion in transactions that have e…
  • Mechera, and Bioheaven. And we are making good progress in maximizing the value of each on…
  • year over year in the US, in the quarter, driven by the strong performance of PATSE. Bring…
  • a broader set of options and more expertise, helping patients and driving growth for Pfize…
  • pipeline at the time we closed the acquisition. In our late-stage development programs, we…
  • expensive clinical development program across our obesity portfolio. We plan to advance 10…
  • peptide berobenatide. We have made significant progress with enrolment across our pivotal …
  • We
  • are working toward the first in a series of potential approvals for berobenatite in 2028. …
  • operationally, driven by underlying demand and excellent commercial execution. We see real…
  • field. We are leading the oral CGRP class in the US and are working to extend that positio…

We are also encouraged by strong adoption when we are able to expand access.

Passages & reports (1)
  • We are also encouraged by strong adoption when we are able to expand access.

Speaker 2

2026 execution in RD has been strong, and we continue to prioritize the highest value opportunities for patients and future growth across our four therapeutic focus areas. Our excellent progress showcases our momentum in advancing our strategy. In recent months, we achieved two key regulatory decisions one key pivotal result, and eight key pivotal study starts, alongside strong data we presented at several recent medical congresses.

We are excited by the pipeline opportunities in areas of
strategic focus and commercial strength. This includes late stage programs across tumor types in oncology, including multiple myeloma, breast cancer, and lung cancer. Within inflammation and immunology, and of course in pneumococcal vaccines. Chris will share more detail about our recent advancement in the recent months. Our pipeline strategy is grounded in discipline prioritization and accelerated execution.

And we are confident that we are advancing our most significant opportunities for future patient impact
and growth. Today, we are raising our guidance for full year 2026 revenue and adjusted earnings per share. This reflects our strong performance through the third quarter and confidence in our ability to execute our strategy. Along with our financial discipline and the progress we continue to make with our RD pipeline, ?we believe Pfizer is well positioned to drive growth towards the end of the decade and create sustained value for patients and shareholders over the long term.

We have deployed AI in our business with the goal of improving efficiency in manufacturing and sharpening how we engage physicians and patients.
In RD, we are working to accelerate innovation with faster target validation and better molecule and biomarket selection. The recent launch of Genesis, ?a new pharmacovigilance platform, shows our commitment to harnessing advanced AI and intelligent automation for global safety monitoring. This typically involves a lengthy manual process for more than 600 products in over 120 countries.

Genesis takes on the
administrative burden so our safety scientists can spend their time where it matters most, assessing causality, detecting safety signals, and protecting patients. With that, I will turn it over to Cecil.

Passages & reports (12)
  • 2026 execution in RD has been strong, and we continue to prioritize the highest value oppo…
  • months, we achieved two key regulatory decisions one key pivotal result, and eight key piv…
  • strategic focus and commercial strength. This includes late stage programs across tumor ty…
  • vaccines. Chris will share more detail about our recent advancement in the recent months. …
  • and growth. Today, we are raising our guidance for full year 2026 revenue and adjusted ear…
  • discipline and the progress we continue to make with our RD pipeline,
  • we
  • believe Pfizer is well positioned to drive growth towards the end of the decade and create…
  • In RD, we are working to accelerate innovation with faster target validation and better mo…
  • a
  • new pharmacovigilance platform, shows our commitment to harnessing advanced AI and intelli…
  • administrative burden so our safety scientists can spend their time where it matters most,…

Speaker 1

Thank you,

Passages & reports (1)
  • Thank you,

Speaker 3

Unverified voice label

Albert, and good morning. I am proud to speak to you today as Pfizer CFO. I'm looking forward to continuing to work alongside the executive leadership team and lead a world-class finance

Passages & reports (1)
  • Albert, and good morning. I am proud to speak to you today as Pfizer CFO. I'm looking forw…

Speaker 1

organization.

Passages & reports (1)
  • organization.

Speaker 3

I am genuinely excited about what we can achieve together, and I will approach this role with financial discipline and a focus on translating Pfizer's scientific and commercial progress into durable shareholder value. I am confident in our strategy, and that as a team we can deliver durable long-term value for our shareholders with rigorous capital allocation and disciplined execution. Now I am pleased to share our third quarter results, which demonstrate continuous commercial execution and financial discipline.

Revenues from our non-COVID product delivered solid growth, while product mix, productivity, and cost management supported margin expansion and enabled continuous investment across a robust pipeline. This year performance
gives us the confidence to raise our full year 2026 revenue guidance as well as raise and narrow our adjusted DUT EPS guidance. Now onto the results.

Passages & reports (4)
  • I am genuinely excited about what we can achieve together, and I will approach this role w…
  • a team we can deliver durable long-term value for our shareholders with rigorous capital a…
  • discipline. Revenues from our non-COVID product delivered solid growth, while product mix,…
  • gives us the confidence to raise our full year 2026 revenue guidance as well as raise and …

2026 revenue of $16.6 billion came in ahead of our expectation, with strong 7% operational revenue growth of our non COVID products, driven by key brands in the US and select international markets, offset by lower revenues from our COVID 19 products.

Passages & reports (2)
  • 2026 revenue of $16.6 billion came in ahead of our expectation, with strong 7% operational…
  • our COVID 19 products.

Speaker unclear

?On

Passages & reports (1)
  • On

Speaker 3

the bottom line, start quarter 2026 reported diluted DPS was 56 cents. In addition, adjusted diluted EPS of 87 cents exceeded our expectation and includes the 10 cent charge related to the innovant transaction. This outperformance reflects cost discipline and improved productivity across the organization, even as we increase investment towards future growth drivers and advance several phase three study starts.

Passages & reports (2)
  • the bottom line, start quarter 2026 reported diluted DPS was 56 cents. In addition, adjust…
  • transaction. This outperformance reflects cost discipline and improved productivity across…

We saw solid revenue contributions in the quarter from Ediquist, PATSEV, the Vindacal family, Nerdek, and Lorraine, while our COVID-19 products and the Pravner family declined in the quarter. Our launched and acquired product contributed $3.8 billion in revenues and grew 32% operationally in the quarter, primarily driven by PATSEV up $255 million, Nartec up $135 million, and Lobrena up $114 million. We continue to invest behind this group of products to mitigate LOE edwinds over the next several years.

In addition, this quarter's performance demonstrates clear progress against our objective of returning to growth towards the end of the decade.

Passages & reports (3)
  • We saw solid revenue contributions in the quarter from Ediquist, PATSEV, the Vindacal fami…
  • in revenues and grew 32% operationally in the quarter, primarily driven by PATSEV up $255 …
  • to invest behind this group of products to mitigate LOE edwinds over the next several year…

Cost discipline and continued optimization across the company, including our manufacturing footprint, remain priorities. We are making meaningful progress with our productivity initiatives and remain on track to deliver nearly all of the anticipated $7.2 billion of net savings by the end of 2026 for our ongoing cost improvement programs. As we announced last quarter, we're initiating the next phase of these programs to deliver an anticipated additional $2.5 billion of net cost savings from 2027 through 2029.

These savings support increased operating efficiency and contribute favorably to our margins. At the same time, we continue to prioritize investment in pipeline programs
that we believe have the greatest potential to deliver meaningful breakthroughs for patients and create long term value for our shareholders. Adjusted gross margin for the third quarter was 77%, primarily reflecting favorable product mix and continued cost management.

Passages & reports (5)
  • Cost discipline and continued optimization across the company, including our manufacturing…
  • of net savings by the end of 2026 for our ongoing cost improvement programs. As we announc…
  • savings from 2027 through 2029. These savings support increased operating efficiency and c…
  • that we believe have the greatest potential to deliver meaningful breakthroughs for patien…
  • product mix and continued cost management.

Speaker unclear

?When

Passages & reports (1)
  • When

Speaker 3

we look at the components of adjusted operating expenses of $6.8 billion, adjusted SINA expenses increased 2% operationally, reflecting in part an increase due to a lower favorable adjustment of US healthcare reform fees year over year offset, partially by lower and targeted marketing and promotional investments toward gross drivers and ongoing cost productivity and improvements. Adjusted RD expenses increased 18% operationally, which includes planned investment in priority, oncology, and obesity programs, including several phase three study stocks.

An acquired in-progress RD decreased 52% operationally, primarily reflecting a $650 million charge related to the innovant transaction this quarter
compared to $1.35 billion charge in the prior year quarter related to the 3S biotransaction. Start quarter 2026 adjusted operating margin was 36%, reflecting effective cost management, strong non COVID revenue performance, higher investment in the business, and I will note was tampered by the AIPRD charge related to the Innovan transaction.

And as I mentioned earlier, third core adjusted diluted EPS was 87
cents.

Passages & reports (6)
  • we look at the components of adjusted operating expenses of $6.8 billion, adjusted SINA ex…
  • partially by lower and targeted marketing and promotional investments toward gross drivers…
  • oncology, and obesity programs, including several phase three study stocks. An acquired in…
  • compared to $1.35 billion charge in the prior year quarter related to the 3S biotransactio…
  • strong non COVID revenue performance, higher investment in the business, and I will note w…
  • cents.

Based on our year-to-day performance, including continued growth across our non-COVID product and disciplined execution, we are raising our full year 2026 revenue guidance by $1.5 billion at the midpoint to a range of 62 to 64 billion dollars. We are reaffirming our expectation of approximately $4 billion for the COVID products with a majority of the community revenues expected in the fourth quarter consistent with the vaccination season.

Passages & reports (2)
  • Based on our year-to-day performance, including continued growth across our non-COVID prod…
  • of 62 to 64 billion dollars. We are reaffirming our expectation of approximately $4 billio…

Speaker 3

In addition, we now expect full year 2026 RD expense to be in the range of 10.8 to $11.8 billion. We are raising and narrowing our full year 2026 adjusted diluted EPS guidance to a range of $2.95 to $3.05. This represents an increase of 10 cents at the midpoint while absorbing the 10 cents per share impact of the innovant transaction. We are reaffirming all other components of our financial guidance.

Passages & reports (3)
  • In addition, we now expect full year 2026 RD expense to be in the range of 10.8 to $11.8 b…
  • $2.95 to $3.05. This represents an increase of 10 cents at the midpoint while absorbing th…
  • our financial guidance.

Our updated outlook reflects our confidence in the non COVID product progress across our cost improvement initiative, an expectation of four-year adjusted growth margin in the mid 70s percent range, and continued investment in our priority pipeline programs. Turning to capital allocation. Our capital allocation priorities remain unchanged. We invest in the business at appropriate returns, maintain and over time grow our dividend, and deliver shareholder returns while preserving flexibility for future value enhancing actions, including share repurchases.

Following the invest innovative transaction, which closed in the start quarter, our current BD capacity is approximately $6 billion.

Passages & reports (3)
  • Our updated outlook reflects our confidence in the non COVID product progress across our c…
  • programs. Turning to capital allocation. Our capital allocation priorities remain unchange…
  • shareholder returns while preserving flexibility for future value enhancing actions, inclu…

In the first month, nine months of 2026, we invested $9.2 billion in internal and external RD and returned $7.3 billion to shareholders through our quarterly dividend. Our start quarter, year year-to-date 2026 operating cash flow was $8.8 billion, and leverage ended the quarter at 2.6 times, slightly below our 2026 target of 2.7 times. Given the impact of upcoming LOEs, we expect leverage to remain around current levels or modestly higher due to the during the LOE transition period.

We remain focused on maintaining a strong financial position while continuing to invest in innovation and support shareholder returns. In conclusion,
I want to leave you with two key takeaways. First, operational excellence. The non-COVID product continued to perform well, growing 7% operationally, and our launch and acquired product grew 32% operational, providing further evidence of our strong capabilities and consistent execution. Second, financial discipline.

We are improving operating efficiency while enabling increased pipeline investment in programs we believe
offers the greatest potential for patients and shareholders. Together, this performance demonstrates that we are executing our strategy, managing the upcoming LOE transition, and strengthen the foundation for a return to growth towards the end of the decade. With that, I'll turn it over to Chris.

Passages & reports (7)
  • In the first month, nine months of 2026, we invested $9.2 billion in internal and external…
  • flow was $8.8 billion, and leverage ended the quarter at 2.6 times, slightly below our 202…
  • higher due to the during the LOE transition period. We remain focused on maintaining a str…
  • I want to leave you with two key takeaways. First, operational excellence. The non-COVID p…
  • providing further evidence of our strong capabilities and consistent execution. Second, fi…
  • offers the greatest potential for patients and shareholders. Together, this performance de…
  • a return to growth towards the end of the decade. With that, I'll turn it over to Chris.

Speaker 4

Unverified voice label

Thanks, Cecile. Across our four therapeutic areas, we made strong progress last quarter. I'll provide colour on recent developments for some of these programs, starting with LREXVIO, our internally discovered BCMA BISP specific, which has now delivered two positive phase 3 readouts in double class exposed multiple myeloma. Most recently, in MM32, LREXVIO monotherapy demonstrated a statistically significant and clinically meaningful improvement in progression free survival versus investigators' choice of three established standard of care regimens.

This is important because the choice of three standard of care regimens provides a robust
representation of how CD38 refractory multiple myeloma is treated today in a patient population that is growing as anti-CD38 therapy moves in the first line setting. And the results themselves were strong. At the time of the interim analysis, more than 75% of patients receiving alrexio had not experienced disease progression or death from any cause.

And the estimated 18-month progression-free survival rate was approximately 68%. Safety in MM32 was consistent with Al RexVio's known profile and also potentially differentiated. With infection prophylaxis measures
incorporated from the start of MM32, rates of grade three or higher infections were lower than those observed in MM5, ?Al RexVio's first positive pivotal trial in double class exposed multiple myeloma. For context, such infection prophylaxis measures were not in place at the start of MM5.

These were instituted following early deaths due to infections that were concentrated in China and two other countries during the
COVID wave, impacting the overall hazard ratio of MM5. MM5 data are expected at a medical meeting before year end and will provide further information on efficacy and safety. Taken together, these positive phase three results from MM32 and MM5 strengthen our confidence in moving LRExphere into earlier lines of treatment.

We are building a compelling case of fixed dose L-Rexphere monotherapy from first relapse, regardless of prior CD38 exposure. And with additional pivotal studies in newly diagnosed multiple myeloma underway, LRExphere's eligible
patient population could grow approximately fivefold, pending clinical and regulatory success. Moving next to a thermocyclip, our potential first-in-class highly selective CDK4 inhibitor, Building on the leadership we established with iBrands, we're advancing a TOMOCyclip as a potential next generation backbone for first line and early HR-positive breast cancer.

Our CAT6 inhibitor, Provetrostat, is being developed in later line settings.
?The TOMOCyclip was designed in-house to improve upon CDK4-6 inhibitors, the current standard of care backbone for HR-positive breast cancer. A key limitation of this class is safety and tolerability, with CDK6 inhibition being a key contributor to adverse events. We designed the thermocyclip to maximize efficacy through greater CDK4 inhibition while improving tolerability by minimizing CDK6 engagement. ?

A
thermocyclip is 33 times more selective for CDK4 versus CDK6, comparing favorably versus the standard of care. Here are two data sets fueling enthusiasm for a thermocyclip. On the left are data presented at ESMA from the phase 2, 4 light 1 study of a termocyclop plus velvestrin in patients with HR-positive HER2-negative breast cancer. All participants had previously received a CDK4-6 inhibitor, and notably, 92% of a Thermocyclop participants were randomized within three months of discontinuing a CDK4-6 inhibitor. ?

The
Thermocyclop regimen reduced the risk of disease progression or death death by 40% compared to investigators' choice of fulvestrant or iferolimus plus XMS stain. These results in a population with highly refractory or resistant disease increase our confidence in our ongoing phase three trial of a thermocyclip versus investigators' choice of CDK4-6 inhibitor in the first-line setting. On the right are data for a thermocyclip's phase two study in early breast cancer.

With a combination of a thermocyclip plus letrozole, 88% of participants' tumors demonstrated complete cell cycle arrest compared to only 18% versus
letrazole alone. These results support our plan to combine a thelmocyclip with a selective estrogen receptor degrader Gyridesterant in a phase three early breast cancer trial expected to initiate within the next few months. This study design has been aligned with regulators building on the expected approval for geridesterant in this setting.

This slide shows 4 light 1 safety and tolerability data alongside results from pivotal studies of the three approved CDK4 6 inhibitors plus foldestrin. These are cross-trial comparisons. Therefore, definitive conclusions cannot be drawn.

Passages & reports (22)
  • Thanks, Cecile. Across our four therapeutic areas, we made strong progress last quarter. I…
  • in MM32, LREXVIO monotherapy demonstrated a statistically significant and clinically meani…
  • representation of how CD38 refractory multiple myeloma is treated today in a patient popul…
  • experienced disease progression or death from any cause. And the estimated 18-month progre…
  • incorporated from the start of MM32, rates of grade three or higher infections were lower …
  • Al
  • RexVio's first positive pivotal trial in double class exposed multiple myeloma. For contex…
  • COVID wave, impacting the overall hazard ratio of MM5. MM5 data are expected at a medical …
  • strengthen our confidence in moving LRExphere into earlier lines of treatment. We are buil…
  • patient population could grow approximately fivefold, pending clinical and regulatory succ…
  • backbone for first line and early HR-positive breast cancer. Our CAT6 inhibitor, Provetros…
  • The
  • TOMOCyclip was designed in-house to improve upon CDK4-6 inhibitors, the current standard o…
  • adverse events. We designed the thermocyclip to maximize efficacy through greater CDK4 inh…
  • A
  • thermocyclip is 33 times more selective for CDK4 versus CDK6, comparing favorably versus t…
  • velvestrin in patients with HR-positive HER2-negative breast cancer. All participants had …
  • The
  • Thermocyclop regimen reduced the risk of disease progression or death death by 40% compare…
  • choice of CDK4-6 inhibitor in the first-line setting. On the right are data for a thermocy…
  • letrazole alone. These results support our plan to combine a thelmocyclip with a selective…
  • geridesterant in this setting. This slide shows 4 light 1 safety and tolerability data alo…

These data further suggests that high CDK4 selectivity drives improved safety and tolerability, enabling continuous dosing, excellent adherence, and potentially greater efficacy. Grade 3 or high in neutropenia was numerically lower with the thermocyclip than with any of the approved agents, with no grade four or five neutropenia reported. Any grade diarrhea was lower than with Abemocyclip and comparable to pulvocyclip and ribocyclip. Dose reductions due to adverse events were 14% with a thermocyclip compared to 32 to 43% with the approved agent.

Turning to tuber,
we are advancing an extensive program for this potentially best in class PD1 VGF bisecific antibody with over 1,200 patients treated globally and a consistent safety profile. This includes two ongoing phase three trials with two additional phase three trials expected to begin this year. Updated results at ESMO strengthen our confidence as we expand Tibonatomics development. Since SITC25, confirmed response rate for the pivotal dose of Tibonatomic plus doublet chemotherapy from the ongoing phase two study have risen by roughly 20 percentage points in non-squamous and squamous first-line non-small cell lung cancer.

They now stand at approximately 80%, exceeding those of Tesla lismap plus chemotherapy in this study. Medium progressive free survival was nearly 14 months for both histologies, an improvement of roughly four to five months versus the
comparators. Notably, Tesla lisimap's efficacy was consistent consistent with historical phase three results for the leading PD1 antibody pembry map, which supports the relevance of the control arms.

We are also encouraged by how Tvanatomic efficacy and safety results compare with phase three data
for the PD1 VGF bispecific antibody ivanisomap, while recognizing the limitations of crosstrial comparisons. Now for INI, Tilrechomic, a potential first-in-class trispecific antibody, Tilrechomic was designed in-house to simultaneously target multiple complementary drivers of type 2 inflammation, IL-4, IL-13, and TSLP. Phase 2 results and atopic derivatitis provide compelling proof of concept.

At the top monthly doses, Tilrechomic treatment led to placebo jazzid response rate of about 50% for EZ75 to find a 75% or greater improvement in the eczema area and
severity index. While cross-trial comparisons have limitations, these phase two data suggest the potential for superiority over dupilomap, the current standard of care biologic. These secondary endpoints in our ongoing phase three program are powered to test this hypothesis in a head to head setting.

For
safety, Torrecomeg demonstrated a favorable profile at subcutaneous doses up to 400 milligrams once every four weeks, the observed frequency of conjunctivitis and injection site reactions were lower than rates reported with Dupillomap and comparable to placebo. Beyond aterpic dermatitis, Telrechomic offers a pipeline and a product opportunity, targeting pathways that are validated by approved therapies across nine different diseases. Late stage studies are underway in severe asthma and moderate to severe COPD.

Moving to our potential best in class pneumococcal conjugate vaccine program, building on
PREFNAS 25 plus year legacy of effectiveness and safety, we're advancing next generation candidates designed for leading serotype and invasive disease coverage. In pediatrics, PCB 25 delivered strong phase two results. All 20 serotypes shared with PREFNA 20 met the twofold post-dose post-dose 4 IgG criterion historically used to establish non-inferiority. Since the pediatric licensure of PREFNA 20 in 2023, the FA established an updated, more stringent, 1.5-fold non-inferiority criterion that is incorporated into our phase three design.

Given the phase two results and tighter confidence intervals expected with a much larger sample size in phase three, modeling predicts this criterion will be met for at least 22 of 25 serotypes in our pivotal study. Taken together with serial response
data, functional OPA T test, and the totality of evidence approach to licensure. These results provide confidence as we aim to deliver a best in class pediatric pneumococcal vaccine protecting against stereotypes that collectively cause an estimated 84% of invasive disease cases in US children under five.

This would represent an incremental increase of approximately 25 percentage points versus PREFNA 20. Our phase three program is well underway with the phase three lot to lot consistently consistency study already fully enrolled. In
adults, PCB 35 extends the enhanced serotype 3 technology we validate it with PCB 25 to other key serotypes with a phase one start expected this year. Looking ahead, we expect a strong cadence of regulatory decisions, data readouts, and pivotal study starts over the next 12 months.

These include a readout from MEFRA 1, which, based on the current event rate is now expected in the first quarter of 2027. If successful, MEFRO 1 could support approval for MEPROMETAS, our in-house discovered potential
first in class EZH2 inhibitor for prostate cancer, expanding our franchise. With that, I'll hand it back to Albert.

Passages & reports (19)
  • These data further suggests that high CDK4 selectivity drives improved safety and tolerabi…
  • Any grade diarrhea was lower than with Abemocyclip and comparable to pulvocyclip and riboc…
  • we are advancing an extensive program for this potentially best in class PD1 VGF bisecific…
  • begin this year. Updated results at ESMO strengthen our confidence as we expand Tibonatomi…
  • non-squamous and squamous first-line non-small cell lung cancer. They now stand at approxi…
  • comparators. Notably, Tesla lisimap's efficacy was consistent consistent with historical p…
  • for the PD1 VGF bispecific antibody ivanisomap, while recognizing the limitations of cross…
  • inflammation, IL-4, IL-13, and TSLP. Phase 2 results and atopic derivatitis provide compel…
  • severity index. While cross-trial comparisons have limitations, these phase two data sugge…
  • safety, Torrecomeg demonstrated a favorable profile at subcutaneous doses up to 400 millig…
  • Telrechomic offers a pipeline and a product opportunity, targeting pathways that are valid…
  • PREFNAS 25 plus year legacy of effectiveness and safety, we're advancing next generation c…
  • twofold post-dose post-dose 4 IgG criterion historically used to establish non-inferiority…
  • incorporated into our phase three design. Given the phase two results and tighter confiden…
  • data, functional OPA T test, and the totality of evidence approach to licensure. These res…
  • US children under five. This would represent an incremental increase of approximately 25 p…
  • adults, PCB 35 extends the enhanced serotype 3 technology we validate it with PCB 25 to ot…
  • pivotal study starts over the next 12 months. These include a readout from MEFRA 1, which,…
  • first in class EZH2 inhibitor for prostate cancer, expanding our franchise. With that, I'l…

Speaker 2

Thank you, Chris. And in closing, operational excellence is driving a commercial momentum across our key growth brands. And I would say importantly, with our launched and acquired products. Our capital allocation strategy, on the other hand, is designed to create long term shareholder value. And our late stage pipeline progress, with a significant number of pivotal readouts expected near term, is strengthening our opportunity to extend our leadership in key areas and make a difference for patients.

I'm confident Pfizer is well positioned for growth towards the end of this decade and for
long term shareholder value creation. We have line of sight to our aim of delivering a risk adjusted high single digit revenue Kager from year end 2028 through year end 2033. Now we will move to QA and operator, please assemble the queue.

Passages & reports (4)
  • Thank you, Chris. And in closing, operational excellence is driving a commercial momentum …
  • stage pipeline progress, with a significant number of pivotal readouts expected near term,…
  • long term shareholder value creation. We have line of sight to our aim of delivering a ris…
  • to QA and operator, please assemble the queue.

Speaker 0

Thank you. If you'd like to ask a question, press star one on your keypad. ?To leave the queue at any time, press star two. Once again, that is star one to ask a question. Our first question today will come from Chris Schott with JP Morgan. Your line is now open.

Passages & reports (3)
  • Thank you. If you'd like to ask a question, press star one on your keypad.
  • To
  • leave the queue at any time, press star two. Once again, that is star one to ask a questio…

Questions & answers

Speaker 5

Unverified voice label

Great. Uh thanks so much for the questions. Um I just had uh two pipeline ones. ?Uh maybe first on the on the tri-specific uh to recommig. ?Uh how are you thinking about the positioning of this one in atopic Durham as we consider ?I guess first line versus second line usage as we were just thinking about you know the very strong data you presented versus a very well-entrenched standard of care.

And maybe just a a second part of that, just talk about the timelines for the indications beyond AD that you're pursuing.
?Uh the second question uh was then just pivoting over to the upcoming phase one two AMLIN and combo data that we're gonna see. ?Uh here, can you just help some set some expectations about how you're thinking about that data and then the type of titration schedule that's being used in that study just to help us kind of frame out what we're gonna see with that with that readout?

Thanks so

Passages & reports (11)
  • Great. Uh thanks so much for the questions. Um I just had uh two pipeline ones.
  • Uh
  • maybe first on the on the tri-specific uh to recommig.
  • Uh
  • how are you thinking about the positioning of this one in atopic Durham as we consider
  • I
  • guess first line versus second line usage as we were just thinking about you know the very…
  • Uh
  • the second question uh was then just pivoting over to the upcoming phase one two AMLIN and…
  • Uh
  • here, can you just help some set some expectations about how you're thinking about that da…

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 2

No, thank you. Chris, would you like to cover the timelines of uh Tri-Specific and of course the Amylin and Berobenatite questions? ?And then maybe Alexander, you can speak a little bit about the commercial positioning.

Passages & reports (3)
  • No, thank you. Chris, would you like to cover the timelines of uh Tri-Specific and of cour…
  • And
  • then maybe Alexander, you can speak a little bit about the commercial positioning.

Speaker 4

Um, thank you very much for the question. So, as you know, we've now started the phase three program for to recommend in atopic dermatitis, two stuff, two studies. One of those those studies includes a head-to-head um against the pillow map, and we also started the phase two, three study, a continuous design for COPD, and phase three studies for severe asthma with expected readouts in 2028 and 2029.

Regarding amylene GLP1, as you're aware, the SOLIS 1 study on as now completely recruited. That is the robustly designed
phase 2B study for amylen single agent and amylene plus berobenatite in different common in different doses and different titrations. We expect the readout for that study for efficacy, the second half of 2027. The ongoing phase one, phase 2A study, um will give an update at the end of this year, recognizing that study was designed for safety and PK, clinical pharmacology, not for efficacy.

Passages & reports (4)
  • Um, thank you very much for the question. So, as you know, we've now started the phase thr…
  • COPD, and phase three studies for severe asthma with expected readouts in 2028 and 2029. R…
  • phase 2B study for amylen single agent and amylene plus berobenatite in different common i…
  • study, um will give an update at the end of this year, recognizing that study was designed…

Speaker 2

Thank you. And then what about the positioning of the tri-specifics? How do you think that?

Passages & reports (1)
  • Thank you. And then what about the positioning of the tri-specifics? How do you think that…

Speaker unclear

?Chris,

Passages & reports (1)
  • Chris,

Speaker 6

Unverified voice label

thanks for the questions. I think uh we all know that this is a very large category. What we have learned learned with RC BINCO and overall dermatology franchises, there is a lot ?of patients profile that requires different types of therapy. And we see that very much with the JAC versus the uh the versus the MAP. And we see that there are some patients that actually move from one to the other, they drop off.

So there's a lot of circulation of those patients. We are building
capabilities across US and internationals, and we see that we are making good progress. So, for instance, as you saw in this quarter, in international, we reached like hundred million combined between our two asset endomatologies for the quarter. So we start having a nice phase. And as I said, as we move into the result of the study, we will be able to actually capture some of those lapsed patients and naive patients with a very specific profile that we are defining.

So first in class, strong efficacy, and clearly unmet medical lead in the category.

Passages & reports (5)
  • thanks for the questions. I think uh we all know that this is a very large category. What …
  • of
  • patients profile that requires different types of therapy. And we see that very much with …
  • capabilities across US and internationals, and we see that we are making good progress. So…
  • result of the study, we will be able to actually capture some of those lapsed patients and…

Speaker 2

Thank you very much. Next question, please.

Passages & reports (1)
  • Thank you very much. Next question, please.

Speaker 0

Our next question comes from Dave Reisinger with Lyric Partners. Please go ahead.

Passages & reports (1)
  • Our next question comes from Dave Reisinger with Lyric Partners. Please go ahead.

Speaker 5

Yes, thanks very

Passages & reports (1)
  • Yes, thanks very

Speaker 7

Unverified voice label

much. And uh I wanted to say congratulations to Cecile on your new role as CFO of Pfizer and look forward to working with you. Uh my question uh is on U.S. net price in the third quarter and going forward. Uh could you comment on any gross to net benefits uh to net sales in the third quarter, including from any 340B scrubbing, and discuss US net price prospects looking forward in the near term.

Thank

Passages & reports (2)
  • much. And uh I wanted to say congratulations to Cecile on your new role as CFO of Pfizer a…
  • to net sales in the third quarter, including from any 340B scrubbing, and discuss US net p…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 1

Thanks very much. First, uh for your uh good wishes. Uh so as it relates to the pricing in Q3, ?uh, with the exception of, as we were expecting, the impact on Ediquist, which started in uh Q3 ?of the January what price decrease, uh, I would say there is not really any very material change into our Ghost Two Nuts dynamics during the third core.

So the performance that we are seeing is for most part driven by strong market performance and volume rather than uh dynamics around
the Ghost Two nets. As we are looking into uh the future, um obviously um not commenting today on 2027, but we will obviously reflect into our guidance for 2027 the various dynamics that we are seeing, being IRA with two of our products entering into the MF in 2027, and any of the dynamics around the 340B impact and changes, including the credit rebate model implemented uh starting in January, and also obviously some of the MFN impacts that we have following the agreement we have with the government.

But as a summary, the performance into Q3 is really a reflection of the strong execution rather than uh dynamics around Ghost to Net that would not um uh continue.

Passages & reports (8)
  • Thanks very much. First, uh for your uh good wishes. Uh so as it relates to the pricing in…
  • uh,
  • with the exception of, as we were expecting, the impact on Ediquist, which started in uh Q…
  • of
  • the January what price decrease, uh, I would say there is not really any very material cha…
  • the Ghost Two nets. As we are looking into uh the future, um obviously um not commenting t…
  • into the MF in 2027, and any of the dynamics around the 340B impact and changes, including…
  • government. But as a summary, the performance into Q3 is really a reflection of the strong…

Speaker 2

Very well, thank you very much. ?Uh, next question, please.

Passages & reports (3)
  • Very well, thank you very much.
  • Uh,
  • next question, please.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from Umar Ravat with Evercore ISI. Your line is now open.

Passages & reports (1)
  • next question comes from Umar Ravat with Evercore ISI. Your line is now open.

Speaker unclear

?Hi

Passages & reports (1)
  • Hi

Speaker 3

guys, thanks for taking my question. Um, Albert, there's clearly been a lot of progress on SGNA improvements over the last couple of years, ?um, and I acknowledge that. Um, it's not step function, but there's been improvement. But then uh I recall Dave before he moved on had mentioned um that majority of the total net cost savings of 7.2 billion will be delivered by the end of 26.

So when I look now back at the Pfizer PL,
I'm seeing SGN and RD was about 24 and a half billion back in 2022. It's about the same in 2026 as well. ?And I acknowledge RD's gone up a bit, SGNA has come back a ?bit, but the broader dynamics on OpEx are still broadly in that $24 to $25 billion camp. And ?I guess how do you think

Passages & reports (10)
  • guys, thanks for taking my question. Um, Albert, there's clearly been a lot of progress on…
  • um,
  • and I acknowledge that. Um, it's not step function, but there's been improvement. But then…
  • I'm seeing SGN and RD was about 24 and a half billion back in 2022. It's about the same in…
  • And
  • I acknowledge RD's gone up a bit, SGNA has come back a
  • bit,
  • but the broader dynamics on OpEx are still broadly in that $24 to $25 billion camp. And
  • I
  • guess how do you think

Speaker unclear

?about that heading into the dividend integrity, the cost lever heading into

Passages & reports (1)
  • about that heading into the dividend integrity, the cost lever heading into

Speaker 7

patent experience?

Passages & reports (1)
  • patent experience?

Speaker unclear

?Thank you.

Passages & reports (1)
  • Thank you.

Speaker 2

Cecil, why don't you take this a question?

Passages & reports (1)
  • Cecil, why don't you take this a question?

Speaker 1

Yeah, so as I mentioned earlier, we are on track to delivering the $7.2 billion of savings that we had implemented as part of ?our first phase of the cost improvement programs. Those savings were in different places, is one uh in our manufacturing um uh footprint or cost, two in RD, but reinvested, and we are indeed increasing our RD investment in order to support uh the pipeline product and programs that we have, in addition to obviously uh the acquisition that we made.

And then on the uh SINA side, mostly coming from the commercial um and marketing expenses, as well as as ESGS. So, what we are seeing today in our operating expenses, and I wouldn't
relate to just the third quarter, which had some one time dynamics that drove the SINA up. We are still expecting, based on guidance, to see a decline in SINA versus last year.

So that's the first piece that I would say. Going forward, we have announced our second phase of
the program with a $2.5 billion of savings, both in SGNA and in uh in our cost of manufacturing, those will translate into savings. So we are expecting to see those translating and mitigating the margin erosion as part of the LOE transition in 2027 to 2029.

Passages & reports (7)
  • Yeah, so as I mentioned earlier, we are on track to delivering the $7.2 billion of savings…
  • our
  • first phase of the cost improvement programs. Those savings were in different places, is o…
  • and programs that we have, in addition to obviously uh the acquisition that we made. And t…
  • relate to just the third quarter, which had some one time dynamics that drove the SINA up.…
  • the program with a $2.5 billion of savings, both in SGNA and in uh in our cost of manufact…
  • 2029.

Speaker 2

Thank you very, very much, Susu. Uh next question.

Passages & reports (1)
  • Thank you very, very much, Susu. Uh next question.

Speaker 0

We'll go next to Akash Tawari with Jeffries. Your line is now open.

Passages & reports (1)
  • We'll go next to Akash Tawari with Jeffries. Your line is now open.

Speaker 7

Hey,

Passages & reports (1)
  • Hey,

Speaker 3

thanks so much. Uh ?just a couple. I know in the spring you had a kind of 45-50 patient biomarker analysis on your stat six. Um, and you

Passages & reports (3)
  • thanks so much. Uh
  • just a
  • couple. I know in the spring you had a kind of 45-50 patient biomarker analysis on your st…

Speaker 7

were going to make a decision on whether to go from stage one to stage two. Is there an update on that program and really how do you think about TARC reduction and biomarker reduction uh to what we've seen with some of the degraders? And then um on your

Passages & reports (1)
  • were going to make a decision on whether to go from stage one to stage two. Is there an up…

Speaker unclear

?uh

Passages & reports (1)
  • uh

Speaker 3

GLP1 AMLIN,

Passages & reports (1)
  • GLP1 AMLIN,

Speaker unclear

?I

Passages & reports (1)
  • I

Speaker 7

think your phase one, two, ?you just updated

Passages & reports (3)
  • think your phase one, two,
  • you just
  • updated

Speaker 3

on CLIN trials uh to 201 patients. I think it was originally planned to be closer to 400. Um, any color on what drove that decision with the AMLIN GLP1 combo with Methera? Thank

Passages & reports (1)
  • on CLIN trials uh to 201 patients. I think it was originally planned to be closer to 400. …

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Chris, both questions goes to you.

Passages & reports (1)
  • Chris, both questions goes to you.

Speaker 4

Okay, so um thank you very much. So the first is on stat six, potentially first in class on stat six programs. Thanks for the question. Um this is an area very important for us for the INI um portfolio. As we previously stated, we've adapted the program to incorporate some additional DDI studies. So we should give you a readout for the stat six later this year.

Um regarding the um amylen and um beribenotite, as I stated earlier, the SOLIS one study is fully recruited. That studies for effect seed reading
?at the end of next year. And the the phase one, two A study was adapted for um the additional PK studies we are doing. ?But there's there's nothing really, nothing material changes in the trial.

Passages & reports (6)
  • Okay, so um thank you very much. So the first is on stat six, potentially first in class o…
  • we should give you a readout for the stat six later this year. Um regarding the um amylen …
  • at
  • the end of next year. And the the phase one, two A study was adapted for um the additional…
  • But
  • there's there's nothing really, nothing material changes in the trial.

Speaker 2

Thank you. Next question, please.

Passages & reports (1)
  • Thank you. Next question, please.

Speaker 0

We'll go next uh Vomol Devon with Guggenheim. Your line is now open.

Passages & reports (1)
  • We'll go next uh Vomol Devon with Guggenheim. Your line is now open.

Speaker unclear

?Great. Thanks for uh taking

Passages & reports (1)
  • Great. Thanks for uh taking

Speaker 3

my questions. So again, maybe on the pipeline. Um

Passages & reports (1)
  • my questions. So again, maybe on the pipeline. Um

Speaker unclear

?one, we noticed that you posted a new phase one trial for

Passages & reports (1)
  • one, we noticed that you posted a new phase one trial for

Speaker 4

your PI3K inhibitor on CTWCO last week. ?Uh heard what you said around a thermocyclib and your cat six. Curious can if you can maybe just talk about ?how you see that asset sort of fitting into your broader breast cancer strategy. And then the other question maybe coming uh from Esmo. ?Uh we saw the Volga data that

Passages & reports (7)
  • your PI3K inhibitor on CTWCO last week.
  • Uh
  • heard what you said around a thermocyclib and your cat six. Curious can if you can maybe j…
  • how
  • you see that asset sort of fitting into your broader breast cancer strategy. And then the …
  • Uh
  • we saw the Volga data that

Speaker 3

AstraZeneca released that ?could suggest maybe less need for, you know, ?the use of fewer cycles of PADSEV in patients with bladder cancer. Curious if you have any sort of reactions to that data set or ?how it might impact how you think the use of PADSEV

Passages & reports (7)
  • AstraZeneca released that
  • could
  • suggest maybe less need for, you know,
  • the
  • use of fewer cycles of PADSEV in patients with bladder cancer. Curious if you have any sor…
  • how
  • it might impact how you think the use of PADSEV

Speaker unclear

?may play out in the future? Thanks.

Passages & reports (1)
  • may play out in the future? Thanks.

Speaker 4

Yes. So firstly on the PI3K, we started to base one study on an internally discovered PIC3CA inhibitor. Reminder that genitalic with salcuity is also Pfizer Pfizer-discovered medicine. We have an ongoing clinical trial with relay with the PIC3CA, alpha um alpha pan-alpha isoform selected inhibitor called Zovigallicip. And the advantage, also in combination with a termocyclip, the advantage of the Thermocyclip is we do not see DDIs, which has been experienced with all the other CDK4-6 inhibitors, combining with the PIC3CA.

So it's a potentially significant advantage to your point, up to 40% of breast cancer, ER
positive breast cancer, up to 20%, 25% of two positive breast cancer will harbor a PIC3CA mutation. So it's an important area for us.

Passages & reports (3)
  • Yes. So firstly on the PI3K, we started to base one study on an internally discovered PIC3…
  • isoform selected inhibitor called Zovigallicip. And the advantage, also in combination wit…
  • positive breast cancer, up to 20%, 25% of two positive breast cancer will harbor a PIC3CA …

Speaker 4

I'll start briefly. Firstly, this reinforces the use of PATSEP for muscle invasive bladder cancer. It reinforces the use of PATSIP in combination with the PD1 for muscle invasive bladder cancer. It also reinforces the confidence we have in the study we've just started, 309, which is bladder-sparing PATSLETSEF Pembroke map in a bladder sparing setting, as well as the ongoing planned phase three trial with PATSLEF plus Kubernetes, which should also start later this year.

I just want to remind on the Volga study, this was a no cisplatin eligible population. Pathological complete remission was lower than what we've
seen with Pembroke plus PATSEP, which is important, including slightly lower event free survival. And most importantly, this is a curative incent setting. So we're not clear yet which patients can be de-escalated. So that's important for physicians. Who can you actually give less therapy to?

Thank you.

Passages & reports (4)
  • I'll start briefly. Firstly, this reinforces the use of PATSEP for muscle invasive bladder…
  • bladder-sparing PATSLETSEF
  • Pembroke map in a bladder sparing setting, as well as the ongoing planned phase three tria…
  • seen with Pembroke plus PATSEP, which is important, including slightly lower event free su…

Speaker 2

Thank you very much. Next question, please.

Passages & reports (1)
  • Thank you very much. Next question, please.

Speaker 0

We'll go next to Evan Siegerman with Bemo Capital Markets. Your line is now open.

Passages & reports (1)
  • We'll go next to Evan Siegerman with Bemo Capital Markets. Your line is now open.

Speaker 7

Hi ?guys. Hi guys.

Passages & reports (3)
  • Hi
  • guys. Hi
  • guys.

Speaker unclear

?Thank you so much for taking my question. Um Cecil, so did you inherit um

Passages & reports (1)
  • Thank you so much for taking my question. Um Cecil, so did you inherit um

Speaker 5

the capital allocation framework kind of established by your predecessor? How do you think about the marginal dollars that you can kind of invest

Passages & reports (1)
  • the capital allocation framework kind of established by your predecessor? How do you think…

Speaker unclear

?from here

Passages & reports (1)
  • from here

Speaker 3

between internal RD,

Passages & reports (1)
  • between internal RD,

Speaker 5

another

Passages & reports (1)
  • another

Speaker 3

bolton you talked about, BD capacity, d-leveraging and eventually restarting buybacks, where do you currently see the highest prospective return for shareholders?

Passages & reports (1)
  • bolton you talked about, BD capacity, d-leveraging and eventually restarting buybacks, whe…

Speaker unclear

?Yes,

Passages & reports (1)
  • Yes,

Speaker 2

Sasu.

Passages & reports (1)
  • Sasu.

Speaker 1

Thanks, Evan. So our priorities are clear and I and they are not changing versus what was in place. I think they are we have a solid plan to get us through LOE and Post LOE. So our priorities invest for growth,

Passages & reports (1)
  • Thanks, Evan. So our priorities are clear and I and they are not changing versus what was …

Speaker 3

maintain our grow our dividend over time, ?and then keep a strong balance. So through the LOE period,

Passages & reports (3)
  • maintain our grow our dividend over time,
  • and
  • then keep a strong balance. So through the LOE period,

Speaker 1

our operating cash flow, financial asset, and access to capital market will give us the ability to continue to invest and maintain the dividend. As we go post-AloE period, our operating cash flow grows with the levers, and we have other options to continue to increase shareholder value. And in that situation, share repurchases become again one of the levers that we have in order to be able to address

Passages & reports (2)
  • our operating cash flow, financial asset, and access to capital market will give us the ab…
  • that situation, share repurchases become again one of the levers that we have in order to …

Speaker 3

uh to continue enhance that shareholder

Passages & reports (1)
  • uh to continue enhance that shareholder

Speaker unclear

?right

Passages & reports (1)
  • right

Speaker 2

thank you very much next question please

Passages & reports (1)
  • thank you very much next question please

Speaker 0

we'll go next to steve scala with td cowan please go ahead

Passages & reports (1)
  • we'll go next to steve scala with td cowan please go ahead

Speaker 7

oh thank ?you two questions given the push out of mevro one were

Passages & reports (3)
  • oh thank
  • you two questions given
  • the push out of mevro one were

Speaker unclear

?there any changes to me pro two

Passages & reports (1)
  • there any changes to me pro two

Speaker 7

and three timelines so that's the first question second question is for Cecile so you started at Pfizer when Warner Lambert was being consolidated, have been through the acquisitions of Pharmacia, Wyeth, and CGIN, and many BD deals, including that for Eloquist. I think it could be argued that Pfizer's most successful products have come through deals. And in each of those years, as it is now, Pfizer viewed its pipeline as very good.

So given this history, why doesn't Pfizer make another big deal its primary focus? Or would you say that the pipeline is significantly better now than at any time in
the last 25 years? Thank

Passages & reports (3)
  • and three timelines so that's the first question second question is for Cecile so you star…
  • Pfizer's most successful products have come through deals. And in each of those years, as …
  • the last 25 years? Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Good question. Cecile, what do you think?

Passages & reports (1)
  • Good question. Cecile, what do you think?

Speaker 1

Thank you. And just for the record, I came with WIES and not uh so don't have the history on all the on all the deals, but uh I think WIES was one of the best acquisitions uh that we did, and I've seen since uh since then uh a transformation of Pfizer uh and a strengthening definitely of our pipeline uh over the last uh 25 years.

Um, so what I would say is in terms of our priorities, right? So we have, as Albert um uh reiterated earlier, we have invested very significantly over the past few years in uh key transactions and key
acquisitions that are today already um kind of like a driving success. We're talking about PATEF, we're talking about Nartec, and we see a lot of opportunities that still remain in the pipeline, in CGEN, in Matsera, so where we have a lot to execute both commercially and um and uh on an RD side and on the commercial side.

So really as we look about uh as we look um at BD going forward and considering our capital allocation priorities, our focus is really on um more bolt-on uh acquisitions uh that are going
to complement uh the large and rich portfolios that we have in the four therapeutic areas that we're having. So looking at a BD acquisition is obviously strategically aligned, building upon our expertise, and then obviously providing the financial returns, appropriate returns that we would be expecting.

Passages & reports (6)
  • Thank you. And just for the record, I came with WIES and not uh so don't have the history …
  • a strengthening definitely of our pipeline uh over the last uh 25 years. Um, so what I wou…
  • acquisitions that are today already um kind of like a driving success. We're talking about…
  • and uh on an RD side and on the commercial side. So really as we look about uh as we look …
  • to complement uh the large and rich portfolios that we have in the four therapeutic areas …
  • we would be expecting.

Speaker unclear

?Thank you,

Passages & reports (1)
  • Thank you,

Speaker 2

Cecil. Chris, you want to comment a little bit on the timelines of uh of Mevro. And uh given the interest on the product, maybe Amir also you say a few things about the potential.

Passages & reports (1)
  • Cecil. Chris, you want to comment a little bit on the timelines of uh of Mevro. And uh giv…

Speaker 4

Um thank you very much. I'll be brief. Um, since we um last spoke about it, the timers have been updated for Methro1 and MEFRO2. A reminder. Um, these are event-driven studies, so it's based on when we expect events to happen. So MEFRA 1 is will now read out Q1 2027 and Methro 2 Q3 2027. And as you've seen with at ESMO, we've got additional data, including compelling um 8.9 months PFS. ?

Um,
just to correct, MEFRA 2 is actually Q4 2027, the updated in critical trials.gov. Thank you.

Passages & reports (4)
  • Um thank you very much. I'll be brief. Um, since we um last spoke about it, the timers hav…
  • Q3 2027. And as you've seen with at ESMO, we've got additional data, including compelling …
  • Um,
  • just to correct, MEFRA 2 is actually Q4 2027, the updated in critical trials.gov. Thank yo…

Speaker 2

Yeah, and I think MEVRO one you expect around February.

Passages & reports (1)
  • Yeah, and I think MEVRO one you expect around February.

Speaker 4

Around February, correct.

Passages & reports (1)
  • Around February, correct.

Speaker 2

This is the projections right now based on uh the way that events are uh are um accruing. Uh and Amir, why are we so excited about Mevro in terms of the commercial opportunity?

Passages & reports (1)
  • This is the projections right now based on uh the way that events are uh are um accruing. …

Speaker 5

I ?think uh three things are ?probably why we're excited. One, uh

Passages & reports (5)
  • I
  • think uh
  • three things are
  • probably why we're
  • excited. One, uh

Speaker 3

we just remind

Passages & reports (1)
  • we just remind

Speaker 5

everybody

Passages & reports (1)
  • everybody

Speaker unclear

?that

Passages & reports (1)
  • that

Speaker 3

uh our current commercial footprint we is anchored in the US around uh alongside Estellus. But MEVRO for us is a fully global opportunity in the US and

Passages & reports (1)
  • uh our current commercial footprint we is anchored in the US around uh alongside Estellus.…

Speaker unclear

?outside the US. So that is

Passages & reports (1)
  • outside the US. So that is

Speaker 3

very significant

Passages & reports (1)
  • very significant

Speaker unclear

?and exciting. Second, uh

Passages & reports (1)
  • and exciting. Second, uh

Speaker 4

as ?Chris mentioned, uh Mevro

Passages & reports (3)
  • as
  • Chris mentioned, uh
  • Mevro

Speaker unclear

?two and three,

Passages & reports (1)
  • two and three,

Speaker 3

across MEVRO 1, 2, and 3, I think we have ?the potential to position MEVRO as a multi-indication franchise. So that gives us lots of surface area to

Passages & reports (3)
  • across MEVRO 1, 2, and 3, I think we have
  • the
  • potential to position MEVRO as a multi-indication franchise. So that gives us lots of surf…

Speaker unclear

?compete

Passages & reports (1)
  • compete

Speaker 6

in.

Passages & reports (1)
  • in.

Speaker unclear

?And finally, if we just think of the total

Passages & reports (1)
  • And finally, if we just think of the total

Speaker 3

patient populations, we're ?talking about over 50,000 in the US, close ?to 50,000 in the EU for and UK, another 14,000 in uh in Japan, and 30%

Passages & reports (5)
  • patient populations, we're
  • talking about over
  • 50,000 in the US, close
  • to
  • 50,000 in the EU for and UK, another 14,000 in uh in Japan, and 30%

Speaker unclear

?of that population could be addressed even

Passages & reports (1)
  • of that population could be addressed even

Speaker 4

with MEVRO

Passages & reports (1)
  • with MEVRO

Speaker 5

one. So there's a significant patient population, a global opportunity, and clearly an area that we have deep commercial ?expertise. Those ?are the things that get us excited about

Passages & reports (5)
  • one. So there's a significant patient population, a global opportunity, and clearly an are…
  • expertise.
  • Those
  • are the
  • things that get us excited about

Speaker unclear

?it.

Passages & reports (1)
  • it.

Speaker 2

Thank you, Amir. And you know, some sometimes people forget that extend, which is one of our very big and strong products, we basically have half of the extended in the US and that's ?it. Uh here we are going to have the whole US and the whole uh global international market. Uh next question please.

Passages & reports (3)
  • Thank you, Amir. And you know, some sometimes people forget that extend, which is one of o…
  • it.
  • Uh here we are going to have the whole US and the whole uh global international market. Uh…

Speaker 0

We'll go next to Jeff Meacham with Citibank. Please go ahead.

Passages & reports (1)
  • We'll go next to Jeff Meacham with Citibank. Please go ahead.

Speaker 5

Great uh morning everyone. Uh thanks so much for the question. Just said two uh the first bigger picture Albert from a a policy a policy perspective I know obviously hard ?to to uh have certainty on especially given today but as you look to twenty twenty seven ?you know, what are your thoughts on the potential risks of changes to MFN or or perhaps greater scrutiny on the prior OUS agreements? ?

Uh
and the second question for for Chris on barabenitide, and you guys have studied,

Passages & reports (7)
  • Great uh morning everyone. Uh thanks so much for the question. Just said two uh the first …
  • to
  • to uh have certainty on especially given today but as you look to twenty twenty seven
  • you know,
  • what are your thoughts on the potential risks of changes to MFN or or perhaps greater scru…
  • Uh
  • and the second question for for Chris on barabenitide, and you guys have studied,

Speaker unclear

?uh, have

Passages & reports (1)
  • uh, have

Speaker 7

started a lot of studies across metabolic indications and and beyond obesity diabetes.

Passages & reports (1)
  • started a lot of studies across metabolic indications and and beyond obesity diabetes.

Speaker 5

Want to get your thoughts on expanding barabenotice as a combo strategy into inflammation or neurocyp

Passages & reports (1)
  • Want to get your thoughts on expanding barabenotice as a combo strategy into inflammation …

Speaker unclear

?or

Passages & reports (1)
  • or

Speaker 7

even ?oncology, for example. That obviously the science is really evolving here on the on GLP1 synergies. Thank

Passages & reports (3)
  • even
  • oncology,
  • for example. That obviously the science is really evolving here on the on GLP1 synergies. …

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

And uh really thank you, Jeff. On on the on the policy perspectives, uh clearly um policy affects a ?lot uh our industry, and we are monitoring it very carefully. ?Uh, we are waiting to see what will happen today in the elections. Uh, but I think that uh in any case, it looks like we will have a uh a split ?uh government. So I don't think that many things can move legislation wise.

I don't expect any changes in MFN. I think the agreements are signed and are going until the end of the term of this government. And
I expect that there will be a renewed interest in the Congress to to investigate several things. But it's uh I don't expect policy changes, frankly. It's a very big contrast vis-a-vis what I was telling you a year ago.

In
2025, I was really scared about uh the implications that either tariffs or MFM could have. I think through the successful navigation of those issues, we brought the stability that it is now projected to last, and uh has brought I think this uh confidence back to the investors to invest in the in the industry in our sector. Now, with that, I will turn it to to Chris to comment on uh the GLP1 and uh and other things.

Passages & reports (10)
  • And uh really thank you, Jeff. On on the on the policy perspectives, uh clearly um policy …
  • lot
  • uh our industry, and we are monitoring it very carefully.
  • Uh,
  • we are waiting to see what will happen today in the elections. Uh, but I think that uh in …
  • uh
  • government. So I don't think that many things can move legislation wise. I don't expect an…
  • I expect that there will be a renewed interest in the Congress to to investigate several t…
  • 2025, I was really scared about uh the implications that either tariffs or MFM could have.…
  • has brought I think this uh confidence back to the investors to invest in the in the indus…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 4

I'll just quickly start. So um our goal is initially to establish berobenatite as a potentially best-in-class monthly subcutaneous GLP1 um for obesity, and this is globally. Um we are starting, as you've seen, additional studies now for knee osteoarthritis as well as for obstructive sleep apnea with or without PAP. And we'll also announce additional phase three studies in the coming months. In 2027, you're absolutely correct.

We hope to announce some additional studies looking at the backbone of our portfolio, including ionite, potentially in oncology. You're right, this is an interesting area. And you'll also see
the acceleration of phase one programs and current programs that's preclinically, that's highly differentiated in this phase. Thank

Passages & reports (3)
  • I'll just quickly start. So um our goal is initially to establish berobenatite as a potent…
  • for obstructive sleep apnea with or without PAP. And we'll also announce additional phase …
  • the acceleration of phase one programs and current programs that's preclinically, that's h…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Very good. Next question,

Passages & reports (1)
  • Very good. Next question,

Speaker unclear

?please. We'll

Passages & reports (1)
  • please. We'll

Speaker 0

go next to Alex Hammett with Wolf Research. Your line is open.

Passages & reports (1)
  • go next to Alex Hammett with Wolf Research. Your line is open.

Speaker unclear

?Thank you.

Passages & reports (1)
  • Thank you.

Speaker 3

Two from me. So as you look at

Passages & reports (1)
  • Two from me. So as you look at

Speaker 0

SIWIN BIOS, GLP1 launched in China, how are both the obesity and the diabetes markets playing out so far? And how is that shaping your thoughts on the commercial opportunity for barobenatide OUS? And then on the Lyme disease vaccine, can you update us on the regulatory path forward following the recent submission in Europe? How are your discussions with FDA progressing? And are there any meaningful differences between FDA and EMA?

Thank

Passages & reports (2)
  • SIWIN BIOS, GLP1 launched in China, how are both the obesity and the diabetes markets play…
  • How are your discussions with FDA progressing? And are there any meaningful differences be…

Speaker unclear

?you. I'm

Passages & reports (1)
  • you. I'm

Speaker 2

not sure I understood the second question.

Passages & reports (1)
  • not sure I understood the second question.

Speaker 4

Lyme disease, Lyme vaccine. Ah,

Passages & reports (1)
  • Lyme disease, Lyme vaccine. Ah,

Speaker 2

the Lyme vaccine. Okay, yes. So, Alexander, thank you, Alex, very much. Alexander, maybe you speak a little bit about our GLP1 in uh China and what to expect from it.

Passages & reports (1)
  • the Lyme vaccine. Okay, yes. So, Alexander, thank you, Alex, very much. Alexander, maybe y…

Speaker 6

Right. So, thanks for the question. As you said, uh Alex, we we've introduced W tide in China ?at the end of April of this year, and we are satisfied with the way we are we are progressing we've learning a lot through the uh through the the launch of uh of echinoglutide in china and the things that we are clearly understanding is there are very different segments within this overall chronic weight management uh categories with patients that ?are all qualifying for uh for the definition of chronic weight management but some of them have more an aesthetic driven purpose with a very different profile of product that they will be looking and their way of acquiring this product is actually very different than the way on the other opposite direction, which ?are very heavy people looking for much more efficacy, tolerability, it becomes a second point point.

And so clearly, what we are learning is it's confirming our strategy that if we want to be successful in point management, you need to have a portfolio. And you need to have a portfolio also because you will need
to activate all those different channels. And the cost of activations of those channels will be advertised across the portfolio. So those are very, very key confirmations of our strategy.

Now, specifically to ignore glutides, as you know, we also understood from the get-go that to be successful in the in chronic weight management in
China in particular, you need two things. ?Of course, you need a good profile, and we have a very competitive profile, but you also need to have type 2 diabetes because it's opened up the hospital channel, but it also opened up for local regulations, the e-commerce channels.

I'm very happy to say that since uh the end of October, we actually got
the approval of type 2 diabetes, which opened up that channel. Second thing, our competitors have also uh access to reimbursements, and this is very important to compete uh effectively. And so I'm also very happy to report that since June we passed the uh NRDL committees, and now we're expecting the final review by the end of this month, so that hopefully we can introduce our product in uh into the overall hospital reimbursement system.

The combination of those two things will really be the start of our penetration of the market.

Passages & reports (14)
  • Right. So, thanks for the question. As you said, uh Alex, we we've introduced W tide in Ch…
  • at
  • the end of April of this year, and we are satisfied with the way we are we are progressing…
  • management uh categories with patients that
  • are
  • all qualifying for uh for the definition of chronic weight management but some of them hav…
  • are
  • very heavy people looking for much more efficacy, tolerability, it becomes a second point …
  • to activate all those different channels. And the cost of activations of those channels wi…
  • China in particular, you need two things.
  • Of
  • course, you need a good profile, and we have a very competitive profile, but you also need…
  • the approval of type 2 diabetes, which opened up that channel. Second thing, our competito…
  • the end of this month, so that hopefully we can introduce our product in uh into the overa…

Speaker 2

Thank you. And from my perspective, it's fascinating to see how the commercial model around the obesity is so different than anything else. And for us, uh reminds us really the times of the Viagra launch because there are a lot of similarities. People are willing to pay out of pocket for products that they value, irrelevant if they are reimbursed or not. That creates dramatically different size in the international markets.

The second was that because of the consumer nature of this launch,
the uh e-commerce and the internet uh, as happened with Viagra, that was the first product that was available basically on the internet, plays a key role. And uh, of course, we are pretty much into that space already, irrelevant if we have already launched an obesity product, because our vaccines and uh and our uh Pax Clovit and our uh uh um

Passages & reports (4)
  • Thank you. And from my perspective, it's fascinating to see how the commercial model aroun…
  • pay out of pocket for products that they value, irrelevant if they are reimbursed or not. …
  • the uh e-commerce and the internet uh, as happened with Viagra, that was the first product…
  • an obesity product, because our vaccines and uh and our uh Pax Clovit and our uh uh um

Speaker 6

biotic.

Passages & reports (1)
  • biotic.

Speaker 2

Excuse me?

Passages & reports (1)
  • Excuse me?

Speaker 6

Biotic

Passages & reports (1)
  • Biotic

Speaker 2

and our uh migraine products, um they are really uh having significant uh channel through the Pfizer for all, which is our consumer uh, let's say uh web uh port to the website. Um so I I I think it's uh we are learning a lot right now in China. Uh after we have learned a lot in our biography. And to add another dimension, AI is changing uh the way that uh promotions are happening right now.

Uh and uh not only at uh physicians level actually even more importantly at the patient's level.
?So uh we are learning a ?lot and uh we are uh very happy that uh uh we are entering this market because I think we it's uh it is cut for our capabilities. With that, I will ask Chris to comment on the Lyme disease.

Passages & reports (6)
  • and our uh migraine products, um they are really uh having significant uh channel through …
  • we have learned a lot in our biography. And to add another dimension, AI is changing uh th…
  • So
  • uh we are learning a
  • lot
  • and uh we are uh very happy that uh uh we are entering this market because I think we it's…

Speaker 4

Um thank you for the question. We all know Lyme disease incidences now, the burden of the disease is increasing globally. The EMA has validated the MA MIA for Pfizer and Valdiva's Lyme disease vaccine candidate. With the validation, um, the CHMP will now begin its assessment of the MAA, and the CA CHMP is expected to issue an opinion on market marketing authorization 2027.

We've also now filed in Canada and we continue our discussions with the FDA and should provide an update regarding this in Q4 um in Q4 this year. Thank you.

Passages & reports (2)
  • Um thank you for the question. We all know Lyme disease incidences now, the burden of the …
  • CHMP is expected to issue an opinion on market marketing authorization 2027. We've also no…

Speaker 2

Alexander, any comments here?

Passages & reports (1)
  • Alexander, any comments here?

Speaker 6

Yeah, no, I I think it's a it's a very exciting opportunity. Just to remind you that we already have an FSME franchise in Europe and we know how to activate tick bonds populations in those endemic areas because we have a sales force, we have a commercial play with pharmacies. And so we are very excited with the opportunity. The level of awareness of the population is significantly higher than what we have in FSME.

So as we have built these muscles commercially, once we have the approval, we're very much looking forward for the opportunity to commercialise this vaccine.

Passages & reports (2)
  • Yeah, no, I I think it's a it's a very exciting opportunity. Just to remind you that we al…
  • very excited with the opportunity. The level of awareness of the population is significant…

Speaker 2

Yeah, and uh the awareness of the disease, of course, in the in the US it's uh skyrocketing right now because we do ?have an increase of severity and incidence. So uh so we are looking forward to uh to concluding the discussion with FDA and submitting our file. Uh let's let's go to the next question, please.

Passages & reports (3)
  • Yeah, and uh the awareness of the disease, of course, in the in the US it's uh skyrocketin…
  • have
  • an increase of severity and incidence. So uh so we are looking forward to uh to concluding…

Speaker 0

Our next question comes from Michael Yi with UBS. Please go ahead.

Passages & reports (1)
  • Our next question comes from Michael Yi with UBS. Please go ahead.

Speaker unclear

?Great, thanks. Uh maybe two quick pipeline

Passages & reports (1)
  • Great, thanks. Uh maybe two quick pipeline

Speaker 7

questions for Chris.

Passages & reports (1)
  • questions for Chris.

Speaker unclear

?Uh on Med Pro, you guys continue to be

Passages & reports (1)
  • Uh on Med Pro, you guys continue to be

Speaker 7

pretty bullish. I know there was ?a uh formulation change to lower the CMAX and improve the tolerability. Maybe you could comment on how you feel about dropouts and the change in formulation to drive uh your effect. And then on to recommend your tri-specific, again, something you're pretty bullish on. Can you just comment on neutralizing antibodies or ADAs, things that can uh uh be tricky for bi-specifics and trispecifics and how you feel about that?

Thank

Passages & reports (4)
  • pretty bullish. I know there was
  • a
  • uh formulation change to lower the CMAX and improve the tolerability. Maybe you could comm…
  • things that can uh uh be tricky for bi-specifics and trispecifics and how you feel about t…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 4

Chris, um, thank you very much. On the first question on meprometostat, um ?uh as you pointed out, we did um for the phase three study adapted to have a more tolerable dose with with food, where we decrease the C max, but see um similar AUC to what we've seen in phase one. So we're very confident of the PK data and the dose that was selected for the phase three study.

Um regarding Tilrigamic, we have not seen functional neutralizing antibodies or functional AD ADAs thus far. You're absolutely correct for any bi-specific or tri-specific, that's a long-term risk. But so far we haven't seen anything impacting efficacy. And in fact,
longer term follow-up on the studies we've previously demonstrated or showed show us that we do not have an impact on efficacy. So so far, so good with um.

Passages & reports (5)
  • Chris, um, thank you very much. On the first question on meprometostat, um
  • uh
  • as you pointed out, we did um for the phase three study adapted to have a more tolerable d…
  • the phase three study. Um regarding Tilrigamic, we have not seen functional neutralizing a…
  • longer term follow-up on the studies we've previously demonstrated or showed show us that …

Speaker 2

Very good. Let's keep it that way if you can, please. Next question, please.

Passages & reports (1)
  • Very good. Let's keep it that way if you can, please. Next question, please.

Speaker 0

Our final question today comes from Assad Hayder with Goldman Sachs. Your line is now open.

Passages & reports (1)
  • Our final question today comes from Assad Hayder with Goldman Sachs. Your line is now open…

Speaker unclear

?Great. Thanks for taking the question and congrats on the quarter, Cecile, and also many congrats and best of luck to you. A couple for you.

Passages & reports (1)
  • Great. Thanks for taking the question and congrats on the quarter, Cecile, and also many c…

Speaker 7

First, just ?on 2027, appreciate the context provided earlier ?on price dynamics with

Passages & reports (5)
  • First, just
  • on 2027,
  • appreciate the context provided earlier
  • on price dynamics
  • with

Speaker unclear

?respect to IRA and 340B, et cetera. But just any additional high level qualitative framing on other pushes and pulls next year to be aware of

Passages & reports (1)
  • respect to IRA and 340B, et cetera. But just any additional high level qualitative framing…

Speaker 7

ahead of formal guidance.

Passages & reports (1)
  • ahead of formal guidance.

Speaker 5

And how should we be thinking about your guidance philosophy relative ?to Dave's

Passages & reports (3)
  • And how should we be thinking about your guidance philosophy relative
  • to
  • Dave's

Speaker unclear

?broadly speaking? And then

Passages & reports (1)
  • broadly speaking? And then

Speaker 7

looking at longer term, you reiterating line of sight to high single digit revenue ?Keger towards the

Passages & reports (3)
  • looking at longer term, you reiterating line of sight to high single digit revenue
  • Keger
  • towards the

Speaker unclear

?end of the decade off of a twenty twenty eight

Passages & reports (1)
  • end of the decade off of a twenty twenty eight

Speaker 7

base, ?uh, as

Passages & reports (3)
  • base,
  • uh,
  • as

Speaker unclear

?well as citing operating leverage and margin

Passages & reports (1)
  • well as citing operating leverage and margin

Speaker 7

expansion given the cost realignment initiatives. ?Uh, but consensus numbers are not really f modeling that. Uh, there does seem to be a disconnect bet on both revenue and the earnings lines versus your own expectations. So as you examine street forecasts, what are the key assumptions that you think are getting most mis mismodelled in the PNL relative to your own internal expectations as you look out

Passages & reports (4)
  • expansion given the cost realignment initiatives.
  • Uh,
  • but consensus numbers are not really f modeling that. Uh, there does seem to be a disconne…
  • internal expectations as you look out

Speaker unclear

?towards that period? Thank you.

Passages & reports (1)
  • towards that period? Thank you.

Speaker 2

Cecil, please make the comments on both.

Passages & reports (1)
  • Cecil, please make the comments on both.

Speaker 1

So thanks, um Asad for your question and also for your good wishes. So we'll provide uh 2027 guidance uh around middle of December, like we did last year. So I will only point out provide high level key drivers that we are seeing in 2027. ?Is one obviously the LOE impact, not only in the US with Ibris and extended and some other products, but

Passages & reports (3)
  • So thanks, um Asad for your question and also for your good wishes. So we'll provide uh 20…
  • Is
  • one obviously the LOE impact, not only in the US with Ibris and extended and some other pr…

Speaker 3

also in international, where we are seeing Eliquist uh being LOE at the end of 2026.

Passages & reports (1)
  • also in international, where we are seeing Eliquist uh being LOE at the end of 2026.

Speaker 1

The other thing that I would say is obviously offsetting that is the ramp up and the launch of our uh the ramp up of our launched and acquired uh portfolio uh which again as you have seen um is uh having a very strong performance and steel opportunity for growth and then obviously uh pricing and uh including MFN and ROA which we will reflect in our guidance and then on our cost um initiative program

Passages & reports (2)
  • The other thing that I would say is obviously offsetting that is the ramp up and the launc…
  • pricing and uh including MFN and ROA which we will reflect in our guidance and then on our…

Speaker 3

that

Passages & reports (1)
  • that

Speaker 1

will

Passages & reports (1)
  • will

Speaker 3

allow us to continue to one invest towards the growth opportunities that we are the growth drivers that we have

Passages & reports (1)
  • allow us to continue to one invest towards the growth opportunities that we are the growth…

Speaker 1

on the SINA marketing and commercial space, and then increase the productivity and deliver savings both on the commercial spend and as well on the general and administrative spend. So that's kind of like the key trends for 2027, but again, more to come as we release guidance later in the ?year. As it relates to our high single digit growth aspiration versus the street, is if you look at where that difference is coming from, it's not really coming from one place on one product.

And so is our growth trajectory either. So what we are seeing as a building block for our growth trajectory are
obviously one is a continued growth of our new and acquired product, not only because the market is still growing, our penetration is still increasing, but also on top of it, we are bringing new indications onto those products in order to be able to continue to address more patients and grow our presence on the market.

The second thing is on the pipeline. So while there are some obvious products that are making a key difference in our view versus a three view, obesity being one, some of the oncology products being one, what I will say is our growth trajectory doesn't rely on one single product or one
single therapeutic area. We have a broad uh portfolio of products, several phase three um uh ongoing as well as uh upcoming catalyst over the 18 to 24 months, which should give confidence to uh the outside uh world also to see the opportunities that we are having in bringing breakthrough uh to patients uh in significant areas of unmed

Passages & reports (7)
  • on the SINA marketing and commercial space, and then increase the productivity and deliver…
  • year.
  • As it relates to our high single digit growth aspiration versus the street, is if you look…
  • obviously one is a continued growth of our new and acquired product, not only because the …
  • the market. The second thing is on the pipeline. So while there are some obvious products …
  • single therapeutic area. We have a broad uh portfolio of products, several phase three um …
  • opportunities that we are having in bringing breakthrough uh to patients uh in significant…

Speaker unclear

?need.

Passages & reports (1)
  • need.

Speaker 2

Thank you, Cecile. And I I would add that me as a CEO, when I see the difference between our internal projections and the street projections, that of course creates to me the urgency to check our assumptions to make sure that in light of different opinions from the analyst, we are correct or not. So we have done that repeatedly. And we came to the conclusion that we tell you that we expect to have a high single digit from 28 to 33, and to know very well where the discrepancies ?are between the products.

And as Cecil
?said, there there are not only on the pipeline, which many analysts they do not cover. So you have the phenomenal that from 12, 13 analysts that are forming the overall performance of the 2031, for some products, only five analysts they have this one and the others they don't. So that's this is something that it is expected in pipeline. But we see also very big discrepancies in already launched a new products, uh, that uh there's a big difference.

I will mention two as uh just examples that I think people need to reevaluate
their assessment. One it is regarding Nurtec, that uh we are already close to two billion dollars this uh the way if you analyze ?it. And uh the street has us almost two and a half by year 2030. So I think there is a discrepancy ?there. Uh I will also mention another example of the L Rex ?field, where for a competing product, the street is forecasting five billions, and for us 600 million.

We aspire to present a profile that is very similar in efficacy and better in uh in uh in uh tolerability and in side
effects. Now remains to be proven, but uh I don't think the 600 million vis-à-vis 5 billions, it is justifiable, even with the current information. So I think that uh as more information is coming for our pipeline and redoubts, I think as more information is coming for the performance actually of the new products and uh that includes new launches and uh acquired products, um I think the street probably will start adjusting uh their numbers and there will be a conversion mostly.

But with that, I think
we come to the end of our call. ?I want to say that I'm very proud of our performance through the third quarter and the execution. And my thanks goes to my Pfizer colleagues. As I visit with our people, and I do that in our labs and in manufacturing sites and in markets across the world, I see a team with tremendous talent, dedication, striving for breakthroughs that change patients' lives.

We look forward to sharing additional updates about our progress. And thank you for joining our call today, and thank you for your interesting fights.

Passages & reports (20)
  • Thank you, Cecile. And I I would add that me as a CEO, when I see the difference between o…
  • So we have done that repeatedly. And we came to the conclusion that we tell you that we ex…
  • are
  • between the products. And as Cecil
  • said,
  • there there are not only on the pipeline, which many analysts they do not cover. So you ha…
  • and the others they don't. So that's this is something that it is expected in pipeline. Bu…
  • their assessment. One it is regarding Nurtec, that uh we are already close to two billion …
  • it.
  • And uh the street has us almost two and a half by year 2030. So I think there is a discrep…
  • there.
  • Uh I will also mention another example of the L Rex
  • field,
  • where for a competing product, the street is forecasting five billions, and for us 600 mil…
  • effects. Now remains to be proven, but uh I don't think the 600 million vis-à-vis 5 billio…
  • I think as more information is coming for the performance actually of the new products and…
  • we come to the end of our call.
  • I
  • want to say that I'm very proud of our performance through the third quarter and the execu…
  • dedication, striving for breakthroughs that change patients' lives. We look forward to sha…

Speaker 0

Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.

Passages & reports (1)
  • Thank you. This brings us to the end of today's meeting. We appreciate your time and parti…
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

2 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 2. Unassigned words: 318. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-16T03:30:13.351Z.
Transcript version v1-f36f66736c8b2bae3055 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.